PDCD1 and renal cell carcinoma: The subcommittee recommend IO-based therapy for first-line treatment of patients with papillary and unclassified RCC, specifically single-agent anti-PD-1 for either subtype with the additional treatment possibilities of ipilimumab/nivolumab combination therapy for the latter.